Alogliptin

Also known as: SYR-322, Trajenta, UNII-JHC049LO86, (R)-2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]methyl]benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile, Alogliptin (free base), ALOGLIPTINE, ALOGLIPTINA

Alogliptin (CAS 850649-61-5) is a compound in the Organic Compounds category listed in the Jingsj chemical database. It has the molecular formula C18H21N5O2 and a molecular weight of 339.392 g/mol. Key properties include a boiling point of 519.2±60.0 °C at 760 mmHg, a density of 1.3±0.1 g/cm3 and a flash point of 267.8±32.9 °C. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 850649-61-5
Jingsj CID: J-1898-4
Molecular Formula: C₁₈H₂₁N₅O₂
Molecular Weight: 339.392 g/mol
Category: Organic Compounds
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Boiling Point	519.2±60.0 °C at 760 mmHg
Density	1.3±0.1 g/cm3
Flash Point	267.8±32.9 °C
Exact Mass	339.169525
PSA	97.05000
LogP	1.84
Vapor Pressure	0.0±1.4 mmHg at 25°C
Refractive Index	1.660

Activity & Biological Data

Additional Information	[1]. Feng J, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50(10):2297-300. [2]. Ta NN, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213(2):429-35. [3]. Asakawa T, et al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009 Jul 17;85(3-4):122-6. [4]. Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602(2-3):448-54. [5]. Kajiwara A, et al. Risk Factors for Adverse Symptoms During Dipeptidyl Peptidase-IV Inhibitor Therapy: A Questionnaire-Based Study Carried Out by the Japan Pharmaceutical Association Drug Event Monitoring Project in Kumamoto Prefecture. Drug Saf. 2013 Oct

Additional Information

[1]. Feng J, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50(10):2297-300. [2]. Ta NN, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213(2):429-35. [3]. Asakawa T, et al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009 Jul 17;85(3-4):122-6. [4]. Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602(2-3):448-54. [5]. Kajiwara A, et al. Risk Factors for Adverse Symptoms During Dipeptidyl Peptidase-IV Inhibitor Therapy: A Questionnaire-Based Study Carried Out by the Japan Pharmaceutical Association Drug Event Monitoring Project in Kumamoto Prefecture. Drug Saf. 2013 Oct

Frequently Asked Questions

What is the CAS number of Alogliptin?

The CAS number of Alogliptin is 850649-61-5.

What are the molecular formula and molecular weight of Alogliptin?

Alogliptin has molecular formula C18H21N5O2 and molecular weight 339.392 g/mol.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Alogliptin (CAS 850649-61-5)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1898-4 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.